Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 24.06.2024
Verve Group SE
First Berlin Equity Research hat ein Research Update zu Verve Group SE
(ISIN: SE0018538068) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 4,10 auf EUR 4,90.
Zusammenfassung:
Die kürzlich umbenannte Verve Group SE hat mit der strategischen Übernahme
der Jun Group, ein [ … ]
Wed, 19.06.2024
LAIQON AG
High debt-to-equity conversion and successful capital increase
Topic: in May, LAIQON's 20/24 convertible showed a 80% conversion rate and
a 5.3% cash capital increase has been placed successfully at a premium.
Both capital measures underpin the investor's appetite for LAIQON's equity
story.
High debt to equity conversion: the conversion windo [ … ]
Tue, 18.06.2024
Flughafen Wien AG
Solid May'24 traffic results kick off strong summer; chg. est.
Topic: FWAG released strong May 2024 traffic results, which came in
slightly above our expectations and signal solid ongoing demand for air
travel.
Solid passenger growth: In May, group passenger numbers rose by 8% yoy to
3.75m, above our estimate of 3.66m. FWAG's main hub (Vienna [ … ]
Fri, 14.06.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and increased the price target from USD 3.60 to
USD 8.50.
Abstract:
Cardiol Therapeutics (Cardiol) announced excellent topline data for its
phase II open-label pilot US study (MAvERI [ … ]
Thu, 13.06.2024
Formycon AG
First Berlin Equity Research has published a research update on Formycon AG
(ISIN: DE000A1EWVY8). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 105.00 to EUR 80.00.
Abstract:
The Formycon share price has fallen by more than 40% since the beginning of
2023, mainly because of lower than expected royalty i [ … ]
Wed, 12.06.2024
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 81,00 auf EUR 113,00.
Zusammenfassung:
Der Nettoinventarwert (NAV) für Q1 stieg um etwa 34% J/J auf €252 Mio.,
blieb aber sei [ … ]
Tue, 11.06.2024
CEL-SCI Corporation
First Berlin Equity Research has published a research update on CEL-SCI
Corporation (ISIN: US1508376076). Analyst Christian Orquera reiterated his
BUY rating and decreased the price target from USD 8.40 to USD 6.20.
Abstract:
CEL-SCI announced a positive outcome of the type B meeting with the US FDA
for Multikine, its lead drug candidate for ad [ … ]
Tue, 11.06.2024
R. STAHL AG
Operating turnaround intact thanks to several structural trends
LNG remains a material mid-term growth opportunity. R. Stahl is the
globally leading provider of explosion protection for LNG tankers,
terminals and liquification/regassification plants (25-75% market shares).
Independence from Russian energy imports lead to a rising demand for LNG [ … ]
Thu, 06.06.2024
Almonty Industries Inc.
Defence spendings drive tungsten demand
As geopolitical tensions continue to rise, the demand for advanced defence
technologies is likely to increase, driving the demand for tungsten armour
which is less regulated than depleted uranium and also considered
“exportable” by the US government. With the world’s longest produci [ … ]
Thu, 06.06.2024
M1 Kliniken AG
First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG
(ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 18,00 auf EUR 28,00.
Zusammenfassung:
Die endgültigen Zahlen für 2023 lagen nahe bei den vorläufigen Werten und
bestäti [ … ]
